麓鹏制药61岁美籍董事长谭芬来年薪239万元，曾就职贝达药业

Core Viewpoint - Lupu Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, focusing on the development of high bioavailability oral drugs for cancer and autoimmune diseases [3]. Financial Performance - The company recorded other income and revenue of RMB 25.536 million, RMB 12.072 million, RMB 6.935 million, and RMB 6.774 million for the years 2023, 2024, and the first halves of 2024 and 2025, respectively [4]. - The net loss for the years 2023 and 2024 was RMB -159.44 million and RMB -3.385 million, while the company is projected to achieve profits of RMB 32.897 million and RMB 35.896 million in the first halves of 2024 and 2025, respectively [4]. Product Pipeline - Lupu Pharmaceutical has established a product pipeline consisting of six major candidate products, with three core assets (LP-168, LP-108, and LP-118) currently in the new drug application and clinical stages [3]. Shareholding Structure - Dr. Tan Fenlai and Dr. Chen Yi, through various entities, control a combined voting power of 21.73% in the company, making them the largest shareholder group [5]. Executive Profile - Dr. Tan Fenlai, the Chairman, CEO, and Chief Medical Officer, has extensive experience in the pharmaceutical industry and has been with the company since June 2018 [8][9]. Executive Compensation - Dr. Tan Fenlai's compensation (excluding share-based payments) for the years 2023, 2024, and the first half of 2025 was RMB 2.249 million, RMB 2.394 million, and RMB 0.923 million, respectively [10].